Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

ELDNEledon Pharmaceuticals, Inc.

Nasdaq · CIK 0001404281
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts326

Identity from submissions API

NameEledon Pharmaceuticals, Inc.
CIK0001404281
TickersELDN
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN000000000
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone949-238-8090
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • Eledon Pharmaceuticals, Inc. (2020-12-16T05:00:00.000Z → 2026-11-16T05:00:00.000Z)
  • Novus Therapeutics, Inc. (2017-02-23T05:00:00.000Z → 2020-12-22T05:00:00.000Z)
  • Tokai Pharmaceuticals Inc (2007-06-18T04:00:00.000Z → 2017-05-04T04:00:00.000Z)
Business address
19800 MACARTHUR BLVD.
SUITE 250
IRVINE
CA
92612
CA
Mailing address
19800 MACARTHUR BLVD.
SUITE 250
IRVINE
CA
92612
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

No Financialist filing articles yet for this CIK.

SEC filings

617 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000921895-26-003175 005-88334 261560873 34 30378
2026-11-12 10-Q 10-Q 0001193125-26-458564 001-36620 261547588 34 11454714 1 1
2026-11-12 8-K 8-K 2.02,9.01 0001193125-26-458378 001-36620 261547007 34 452079 1 1
2026-10-30 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002100119-26-001561 005-88334 261505524 34 7744
2026-09-04 S-8 S-8 0001193125-26-383824 333-298779 261362825 33 255414 1 1
2026-08-13 10-Q 10-Q 0001193125-26-349314 001-36620 261274045 34 10797542 1 1
2026-08-13 8-K 8-K 2.02,9.01 0001193125-26-349170 001-36620 261273353 34 430027 1 1
2026-08-04 4 4 0001193125-26-333136 6603
2026-08-04 4 4 0001193125-26-333133 6556
2026-07-31 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002100119-26-001370 005-88334 261225989 34 7642
2026-06-22 8-K 8-K 5.03,5.07,9.01 0001193125-26-277653 001-36620 261107927 34 193890 1 1
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000921895-26-001390 005-88334 26987231 34 30238
2026-05-13 10-Q 10-Q 0001193125-26-221702 001-36620 26973650 34 9358189 1 1
2026-05-13 8-K 8-K 2.02,9.01 0001193125-26-221658 001-36620 26973460 34 378332 1 1
2026-05-11 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-001576 333-295498 26965525 33 1966
2026-05-07 CORRESP filename1.htm 0001193125-26-212858 6554
2026-05-07 UPLOAD filename1.pdf 0000000000-26-004691 333-295498 150220
2026-05-01 S-3 S-3 0001193125-26-201426 333-295498 26932546 33 1317801 1 1
2026-04-30 DEFA14A DEFA14A 0001193125-26-197775 001-36620 26926999 34 3134224 1 1
2026-04-30 ARS ARS 0001193125-26-197765 001-36620 26926947 34 2927294
2026-04-30 DEF 14A DEF 14A 0001193125-26-197732 001-36620 26926777 34 6711501 1 1
2026-04-27 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-001685 005-88334 26901058 34 11021
2026-04-21 PRE 14A PRE 14A 0001193125-26-164367 001-36620 26876229 34 6146754 1 1
2026-03-26 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-001125 005-88334 26799884 34 7382
2026-03-19 10-K 10-K 0001193125-26-116164 001-36620 26775107 34 17567906 1 1
2026-03-19 8-K 8-K 2.02,9.01 0001193125-26-116154 001-36620 26775071 34 371361 1 1
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001346824-26-000041 005-88334 26642052 34 12887
2026-02-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-26-015219 005-88334 26633011 34 19628
2026-01-21 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0002012383-26-000664 005-88334 26545828 34 10984
2026-01-16 4 4 0001193125-26-015489 6978
2026-01-16 4 4 0001193125-26-015488 6969
2026-01-16 4 4 0001193125-26-015487 6975
2026-01-16 4 4 0001193125-26-015486 6972
2026-01-16 4 4 0001193125-26-015485 6960
2026-01-16 4 4 0001193125-26-015484 6990
2026-01-02 8-K 8-K 3.02,9.01 0001193125-26-000968 001-36620 26502782 34 311942 1 1
2025-11-24 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-115374 005-88334 251512481 34 27985
2025-11-14 8-K 8-K 2.02,9.01 0001193125-25-283294 001-36620 251488142 34 516589 1 1
2025-11-14 10-Q 10-Q 0001193125-25-283275 001-36620 251488034 34 12648794 1 1
2025-11-13 8-K 8-K 1.01,9.01 0001193125-25-278392 001-36620 251475081 34 618338 1 1
2025-11-13 424B5 424B5 0001193125-25-278390 333-282260 251475073 33 531903
2025-11-12 424B5 424B5 0001193125-25-275606 333-282260 251468163 33 532971
2025-11-07 8-K 8-K 2.02,7.01,9.01 0001193125-25-270286 001-36620 251459958 34 236972 1 1
2025-08-14 10-Q 10-Q 0001193125-25-180906 001-36620 251220916 34 11702880 1 1
2025-08-14 10-Q/A 10-Q/A 0001193125-25-180904 001-36620 251220871 34 11107020 1 1
2025-08-14 10-K/A 10-K/A 0001193125-25-180865 001-36620 251220372 34 19949453 1 1
2025-08-14 8-K 8-K 2.02,4.02,9.01 0001193125-25-180820 001-36620 251219909 34 474473 1 1
2025-08-06 8-K 8-K 7.01,9.01 0000950170-25-103975 001-36620 251189421 34 217234 1 1
2025-07-29 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000932471-25-000874 005-88334 251159901 34 6381
2025-07-17 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0002052113-25-003025 005-88334 251132191 34 10933
2025-06-12 8-K 8-K 5.03,5.07,9.01 0000950170-25-085588 001-36620 251043919 34 221016 1 1
2025-05-14 10-Q 10-Q 0000950170-25-071582 001-36620 25946862 34 9570918 1 1
2025-05-14 8-K 8-K 2.02,9.01 0000950170-25-071370 001-36620 25945351 34 395028 1 1
2025-04-29 ARS ARS 0000950170-25-060324 001-36620 25889223 34 3139084
2025-04-29 DEFA14A DEFA14A 0000950170-25-060316 001-36620 25889066 34 1148428
2025-04-29 DEF 14A DEF 14A 0000950170-25-060299 001-36620 25888950 34 10594200 1 1
2025-04-14 PRE 14A PRE 14A 0000950170-25-053771 001-36620 25836669 34 10516129 1 1
2025-04-14 8-K/A 8-K/A 4.01,9.01 0000950170-25-053765 001-36620 25836621 34 169795 1 1
2025-04-07 8-K 8-K 4.01,9.01 0000950170-25-051663 001-36620 25818867 34 204542 1 1
2025-03-20 10-K 10-K 0000950170-25-042754 001-36620 25757334 34 19379830 1 1
2025-03-20 8-K 8-K 2.02,9.01 0000950170-25-042644 001-36620 25756440 34 387791 1 1
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001172661-25-001292 005-88334 25631296 34 10825
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-003986 005-88334 25625048 34 58126
2025-01-13 4 4 0000950170-25-004925 7758
2025-01-13 4 4 0000950170-25-004924 7761
2025-01-13 4 4 0000950170-25-004923 8575
2025-01-13 4 4 0000950170-25-004918 8600
2025-01-13 4 4 0000950170-25-004922 7750
2025-01-13 4 4 0000950170-25-004921 8584
2025-01-13 4 4 0000950170-25-004916 8557
2025-01-13 4 4 0000950170-25-004915 7733
2025-01-13 4 4 0000950170-25-004920 7721
2025-01-13 4 4 0000950170-25-004914 7764
2024-12-20 8-K 8-K 5.02,9.01 0000950170-24-138782 001-36620 241565154 34 151540 1 1
2024-11-22 4 4 0000950170-24-130275 6043
2024-11-22 4 4 0000950170-24-130278 6086
2024-11-22 4 4 0000950170-24-130273 6059
2024-11-22 4 4 0000950170-24-130272 6082
2024-11-14 SC 13G/A armistice-eldn093024a1.htm 0001172661-24-005294 005-88334 241463758 34 90825
2024-11-12 10-Q 10-Q 0000950170-24-125622 001-36620 241449584 34 9789923 1 1
2024-11-12 8-K 8-K 2.02,9.01 0000950170-24-125340 001-36620 241447937 34 372931 1 1
2024-11-05 SC 13G SC 13G 0001104659-24-114322 005-88334 241427725 34 77419
2024-11-05 SC 13G SC 13G 0001193125-24-251059 005-88334 241426359 34 325167
2024-10-31 4 OWNERSHIP DOCUMENT 0000921895-24-002408 60796
2024-10-31 SC 13G/A AMENDMENT NO. 10 TO SCHEDULE 13G 0000921895-24-002407 005-88334 241416402 34 289991
2024-10-31 SC 13G/A AMENDMENT NO. 9 TO SCHEDULE 13G 0000921895-24-002406 005-88334 241416398 34 290096
2024-10-30 424B5 424B5 0001193125-24-246779 333-282260 241407342 33 459301
2024-10-30 424B5 424B5 0001193125-24-246773 333-282260 241407288 33 459720
2024-10-30 8-K 8-K 1.01,7.01,9.01 0000950170-24-118497 001-36620 241407163 34 956749 1 1
2024-10-29 8-K 8-K 7.01,9.01 0000950170-24-117946 001-36620 241402726 34 199518 1 1
2024-10-02 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-10-02 10:00:00 9999999995-24-003069 333-282260 241349720 33 1974
2024-10-01 8-K 8-K 3.02 0000950170-24-110857 001-36620 241343695 34 147520 1 1
2024-09-30 CORRESP filename1.htm 0000950170-24-110267 10829
2024-09-26 UPLOAD filename1.pdf 0000000000-24-010968 333-282260 40335
2024-09-20 8-K 8-K 1.01,9.01 0000950170-24-108465 001-36620 241314018 34 157343 1 1
2024-09-20 S-3 S-3 0001193125-24-222880 333-282260 241313600 33 1334902
2024-08-19 10-Q 10-Q 0000950170-24-098590 001-36620 241221145 34 8712439 1 1
2024-08-19 10-Q/A 10-Q/A 0000950170-24-098582 001-36620 241221098 34 7818366 1 1
2024-08-19 10-K/A 10-K/A 0000950170-24-098575 001-36620 241221021 34 15985409 1 1
2024-08-14 8-K 8-K 2.02,4.02,9.01 0000950170-24-097206 001-36620 241209526 34 209941 1 1
2024-08-14 NT 10-Q NT 10-Q 0000950170-24-097200 001-36620 241209482 34 96801
2024-07-12 8-K 8-K 4.01,9.01 0000950170-24-083220 001-36620 241114832 34 165301 1 1
2024-07-10 8-K 8-K 3.02 0000950170-24-082739 001-36620 241110412 34 147228 1 1
2024-07-10 8-K 8-K 5.02,5.07,8.01,9.01 0000950170-24-082730 001-36620 241110364 34 363905 1 1
2024-06-14 4 4 0000950170-24-073772 6068
2024-06-14 4 4 0000950170-24-073771 6034
2024-06-14 4 4 0000950170-24-073770 6051
2024-06-14 4 4 0000950170-24-073767 6076
2024-06-06 424B3 424B3 0001193125-24-156034 333-279711 241024937 33 178708
2024-06-05 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-06-05 10:00:00 9999999995-24-001759 333-279711 241023757 33 1974
2024-06-03 CORRESP filename1.htm 0000950170-24-067759 10489
2024-05-30 UPLOAD filename1.pdf 0000000000-24-006252 333-279711 40525
2024-05-30 ARS ARS 0000950170-24-066631 001-36620 241005705 34 2912105
2024-05-30 DEFA14A DEFA14A 0000950170-24-066587 001-36620 241005452 34 1701110
2024-05-30 DEF 14A DEF 14A 0000950170-24-066564 001-36620 241005175 34 6476954 1 1
2024-05-24 S-3 FORM S-3 0001193125-24-147011 333-279711 24984155 33 271625
2024-05-23 D xslFormDX01/primary_doc.xml 06b 0001404281-24-000002 021-514042 24974914 33 17171
2024-05-15 10-Q 10-Q 0000950170-24-060025 001-36620 24947091 34 6325713 1 1
2024-05-13 4 OWNERSHIP DOCUMENT 0000921895-24-001131 70831
2024-05-13 8-K 8-K 2.02,9.01 0000950170-24-058706 001-36620 24939556 34 329236 1 1
2024-05-07 8-K 8-K 1.01,3.02,7.01,9.01 0000950170-24-053934 001-36620 24919593 34 1236708 1 1
2024-04-26 10-K/A 10-K/A 0000950170-24-049277 001-36620 24884939 34 2792371 1 1
2024-03-28 10-K 10-K 0000950170-24-038091 001-36620 24799595 34 12870749 1 1
2024-03-28 8-K 8-K 2.02,9.01 0000950170-24-038008 001-36620 24798674 34 328171 1 1
2024-02-14 SC 13G armistice-eldn123123.htm 0001172661-24-001341 005-88334 24636912 34 90774
2024-02-14 SC 13G/A AMENDMENT NO. 3 0000929638-24-000642 005-88334 24636496 34 84358
2024-02-14 SC 13G/A AMENDMENT NO. 8 TO SCHEDULE 13G 0000921895-24-000452 005-88334 24633467 34 288628
2023-11-09 10-Q 10-Q 0000950170-23-062203 001-36620 231393545 34 7118421 1 1
2023-11-09 8-K 8-K 2.02,9.01 0000950170-23-062007 001-36620 231392253 34 386752 1 1
2023-11-02 8-K 8-K 7.01,9.01 0000950170-23-058279 001-36620 231372868 34 8431073 1 1
2023-10-03 4 FORM 4 SUBMISSION 0001209191-23-051460 5584
2023-10-03 4 FORM 4 SUBMISSION 0001209191-23-051456 5629
2023-10-02 3 FORM 3 SUBMISSION 0001209191-23-051161 7114
2023-10-02 3 FORM 3 SUBMISSION 0001209191-23-051131 7168
2023-10-02 8-K 8-K 5.02 0000950170-23-050925 001-36620 231297725 34 161379 1 1
2023-09-21 8-K 8-K 5.02,9.01 0000950170-23-049046 001-36620 231267501 34 339915 1 1
2023-09-13 8-K 8-K 5.02 0000950170-23-047951 001-36620 231253183 34 161325 1 1
2023-08-11 S-8 S-8 0000950170-23-041515 333-273900 231161023 33 300233
2023-08-10 10-Q 10-Q 0000950170-23-041456 001-36620 231160480 34 7829413 1 1
2023-08-10 8-K 8-K 2.02,9.01 0000950170-23-040949 001-36620 231157146 34 422441 1 1
2023-06-22 8-K 8-K 5.02,5.07,9.01 0000950170-23-029259 001-36620 231031242 34 405033 1 1
2023-06-08 424B3 424B3 0001193125-23-163490 333-272052 231001882 33 217984
2023-06-02 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-06-02 10:00:00 9999999995-23-001622 333-272052 23991107 33 1924
2023-05-31 CORRESP filename1.htm 0001193125-23-157490 6222
2023-05-24 UPLOAD filename1.pdf 0000000000-23-005538 40491
2023-05-22 D xslFormDX01/primary_doc.xml 06b 0001404281-23-000002 021-482292 23943612 33 16527
2023-05-18 S-3 S-3 0001193125-23-148292 333-272052 23937041 33 311980
2023-05-11 10-Q 10-Q 0000950170-23-021372 001-36620 23912102 34 5599500 1 1
2023-05-11 8-K 8-K 2.02,9.01 0000950170-23-021198 001-36620 23910852 34 388062 1 1
2023-05-09 4 OWNERSHIP DOCUMENT 0000921895-23-001098 67701
2023-05-02 4 FORM 4 SUBMISSION 0001209191-23-026734 5743
2023-05-02 4 FORM 4 SUBMISSION 0001209191-23-026733 5717
2023-05-02 4 FORM 4 SUBMISSION 0001209191-23-026732 5729
2023-05-02 4 FORM 4 SUBMISSION 0001209191-23-026731 5569
2023-05-02 4 FORM 4 SUBMISSION 0001209191-23-026730 5737
2023-05-02 4 FORM 4 SUBMISSION 0001209191-23-026728 5605
2023-05-02 4 FORM 4 SUBMISSION 0001209191-23-026727 5609
2023-05-02 4 FORM 4 SUBMISSION 0001209191-23-026725 5634
2023-05-02 4 FORM 4 SUBMISSION 0001209191-23-026724 5581
2023-05-02 4 FORM 4 SUBMISSION 0001209191-23-026721 5605
2023-05-01 DEF 14A DEF 14A 0000950170-23-016306 001-36620 23874603 34 8244620 1 1
2023-05-01 ARS ARS 0000950170-23-016305 001-36620 23874596 34 1653417
2023-05-01 DEFA14A DEFA14A 0000950170-23-016299 001-36620 23874539 34 1397742
2023-05-01 8-K 8-K 1.01,3.02,5.02,7.01,9.01 0000950170-23-016017 001-36620 23870003 34 2253960 1 1
2023-03-30 10-K 10-K 0000950170-23-011011 001-36620 23781555 34 11641125 1 1
2023-03-30 8-K 8-K 2.02,9.01 0000950170-23-010924 001-36620 23780605 34 798249 1 1
2023-02-14 SC 13G/A schedule13ga.htm 0000929638-23-000549 005-88334 23627627 34 86213
2023-02-02 4 FORM 4 SUBMISSION 0001209191-23-006364 5695
2023-02-02 4 FORM 4 SUBMISSION 0001209191-23-006359 5502
2023-02-02 4 FORM 4 SUBMISSION 0001209191-23-006355 5542
2023-02-02 4 FORM 4 SUBMISSION 0001209191-23-006351 5585
2023-02-02 4 FORM 4 SUBMISSION 0001209191-23-006345 5514
2023-02-02 4 FORM 4 SUBMISSION 0001209191-23-006339 5537
2023-02-02 4 FORM 4 SUBMISSION 0001209191-23-006329 5539
2023-02-02 4 FORM 4 SUBMISSION 0001209191-23-006324 8499
2023-02-02 4 FORM 4 SUBMISSION 0001209191-23-006309 5724
2023-02-02 4 FORM 4 SUBMISSION 0001209191-23-006300 5715
2023-01-09 8-K 8-K 7.01,9.01 0000950170-23-000465 001-36620 23516786 34 16438191 1 1
2022-11-23 4 FORM 4 SUBMISSION 0001209191-22-058608 4964
2022-11-14 10-Q 10-Q 0000950170-22-025007 001-36620 221387497 34 6149688 1 1
2022-11-14 8-K 8-K 2.02,9.01 0000950170-22-024980 001-36620 221385062 34 950960 1 1
2022-08-11 10-Q 10-Q 0000950170-22-016935 001-36620 221156800 34 6909147 1 1
2022-08-11 8-K 8-K 2.02,9.01 0000950170-22-016850 001-36620 221155676 34 443478 1 1
2022-06-23 8-K 8-K 5.07 0000950170-22-011978 001-36620 221033141 34 186495 1 1
2022-05-31 8-K 8-K 7.01,8.01,9.01 0000950170-22-010890 001-36620 22980368 34 2288053 1 1
2022-05-12 10-Q 10-Q 0001564590-22-019921 001-36620 22918803 34 4858866 1 1
2022-05-12 8-K 8-K 2022 Q1 2.02,9.01 0001564590-22-019851 001-36620 22917805 34 392293 1 1
2022-04-28 DEFA14A DEFA14A 0001564590-22-016521 001-36620 22868163 34 620278
2022-04-28 DEF 14A DEF 14A 0001564590-22-016509 001-36620 22867854 34 1650976
2022-03-24 10-K 10-K 0001564590-22-011698 001-36620 22767333 34 13156476 1 1
2022-03-24 8-K 8-K 2.02,9.01 0001564590-22-011680 001-36620 22766542 34 399169 1 1
2022-02-14 SC 13G/A schedule13g.htm 0000929638-22-000470 005-88334 22630046 34 87077
2022-02-11 SC 13G/A ELEDON PHARMACEUTICALS, INC. 0000902664-22-001492 005-88334 22616698 34 50677
2022-02-10 SC 13G/A ELEDON PHARMACEUTICALS, INC. 0000902664-22-001334 005-88334 22611359 34 106907
2022-02-09 SC 13G/A filing.txt 0000315066-22-000854 005-88334 22604179 34 8618
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006492 5707
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006489 5724
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006486 5695
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006485 5502
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006480 5543
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006476 5585
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006471 5514
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006466 5537
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006464 5539
2022-02-02 4 FORM 4 SUBMISSION 0001209191-22-006446 5715
2022-01-31 3 xslF345X02/form307422010_01312022.xml 0001193805-22-000135 45152
2022-01-28 SC 13G/A AMENDMENT NO. 7 TO SCHEDULE 13G 0000921895-22-000268 005-88334 22569403 34 284841
2022-01-26 SC 13G/A eledonpharm13g.htm 0000935836-22-000036 005-88334 22558340 34 59872
2022-01-13 8-K 8-K FOR BVF COMMON SHARE EXCHANGE AGREEMENT 3.02,9.01 0001564590-22-001203 001-36620 22529052 34 228003 1 1
2022-01-11 SC 13G/A sc13ga607422eldn_01102022.htm 0000921895-22-000117 005-88334 22522237 34 284789
2022-01-11 SC 13G/A AMENDMENT NO. 5 TO THE SCHEDULE 13G 0000921895-22-000116 005-88334 22522227 34 284625
2021-12-21 4 FORM 4 SUBMISSION 0000899243-21-049171 4966
2021-11-12 10-Q 10-Q 0001564590-21-056417 001-36620 211399329 34 6992757 1 1
2021-11-12 8-K 8-K FOR Q3'21 EARNINGS RELEASE 2.02,9.01 0001564590-21-056413 001-36620 211399293 34 460665 1 1
2021-09-09 SC 13G/A eledonpharm13g.htm 0000935836-21-000506 005-88334 211243978 34 60843
2021-08-19 4 FORM 4 SUBMISSION 0001209191-21-052519 5348
2021-08-12 10-Q 10-Q 0001564590-21-044038 001-36620 211168526 34 6307282 1 1
2021-08-12 8-K 8-K 2.02,9.01 0001564590-21-043944 001-36620 211167367 34 462747 1 1
2021-08-02 8-K 8-K 5.02 0001564590-21-039644 001-36620 211134872 34 169367 1 1
2021-07-09 3 FORM 3 SUBMISSION 0000899243-21-028049 8250
2021-07-02 8-K 8-K 5.02 0001564590-21-035584 001-36620 211068078 34 170929 1 1
2021-06-16 8-K 8-K 5.07 0001564590-21-033187 001-36620 211021414 34 192620 1 1
2021-06-14 4 FORM 4 SUBMISSION 0000899243-21-023640 5402
2021-06-10 4 FORM 4 SUBMISSION 0000899243-21-022998 5002
2021-05-21 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2021-05-21 17:30:00 9999999995-21-002058 333-254890 21950967 33 1924
2021-05-21 S-3/A S-3/A 0001193125-21-169408 333-254890 21950048 33 59479
2021-05-18 CORRESP filename1.htm 0001193125-21-165620 6766
2021-05-14 10-Q 10-Q 0001564590-21-027695 001-36620 21921166 34 4975598 1
2021-05-13 8-K 8-K 2.02,9.01 0001564590-21-027581 001-36620 21919975 34 248996
2021-05-04 4 FORM 4 SUBMISSION 0000899243-21-018105 5799
2021-04-29 DEFA14A DEFA14A 0001564590-21-022019 001-36620 21871380 34 228549
2021-04-29 DEF 14A DEF 14A 0001564590-21-022013 001-36620 21871293 34 1221613
2021-04-27 8-K 8-K 8.01,9.01 0001564590-21-020624 001-36620 21855501 34 76615
2021-04-20 3 FORM 3 SUBMISSION 0000899243-21-016352 7073
2021-04-12 S-8 S-8 0001193125-21-111836 333-255173 21819139 33 187944
2021-04-05 UPLOAD filename1.pdf 0000000000-21-004037 40424
2021-03-31 S-3 S-3 0001193125-21-101240 333-254890 21789759 33 1344941
2021-03-31 10-K 10-K 0001564590-21-016828 001-36620 21789384 34 12006974 1
2021-03-19 3 FORM 3 SUBMISSION 0000899243-21-012708 8415
2021-03-15 8-K 8-K 5.02 0001564590-21-013094 001-36620 21740990 34 36543
2021-02-16 SC 13G woodline-eldn123120.htm 0001172661-21-000765 005-88334 21639519 34 54298
2021-02-16 SC 13G/A AMENDMENT NO. 4 TO THE SCHEDULE 13G 0000921895-21-000474 005-88334 21638713 34 303212
2021-02-16 SC 13G/A eledon13ga2-021621.htm 0001013594-21-000165 005-88334 21636906 34 74372
2021-02-08 SC 13G filing.txt 0000315066-21-001179 005-88334 21599724 34 8547
2021-01-07 8-K 8-K 3.02,9.01 0001193125-21-003750 001-36620 21513015 34 306709 1 1
2021-01-05 SC 13D/A AMENDMENT NO. 8 0000947871-21-000013 005-88334 21506311 34 78498
2021-01-05 8-K FORM 8-K 5.03,8.01,9.01 0001104659-21-000921 001-36620 21505527 34 414840 1 1
2021-01-04 SC 13G ELEDON PHARMACEUTICALS, INC. 0000902664-21-000010 005-88334 21501823 34 108927
2021-01-04 SC 13G schedule13g.htm 0000929638-21-000023 005-88334 21501758 34 90373
2020-12-30 SC 13G/A AMENDMENT NO. 3 TO THE SCHEDULE 13G 0000921895-20-003303 005-88334 201426832 34 292645
2020-12-28 SC 13G/A AMENDMENT NO. 2 TO THE SCHEDULE 13G 0000921895-20-003279 005-88334 201419103 34 293179
2020-12-28 4 OWNERSHIP DOCUMENT 0000921895-20-003278 59364
2020-12-22 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2020-12-22 16:00:00 9999999995-20-003635 333-251305 201409662 33 1816
2020-12-22 424B2 424B2 0001193125-20-324618 333-251305 201408649 33 154998
2020-12-22 8-K 8-K 5.07 0001193125-20-323914 001-36620 201406096 34 181591 1 1
2020-12-17 CORRESP filename1.htm 0001193125-20-320049 6095
2020-12-16 UPLOAD filename1.pdf 0000000000-20-012123 40290
2020-12-14 3 FORM 3 SUBMISSION 0000899243-20-033730 8094
2020-12-11 S-3 S-3 0001193125-20-315955 333-251305 201383972 33 228910
2020-12-10 8-K 8-K 5.03 0001564590-20-056746 001-36620 201381288 34 35991
2020-12-10 DEFA14A DEFA14A 0001193125-20-314322 001-36620 201379356 34 33672
2020-12-04 4 xslF345X03/ownership.xml 0000947871-20-000933 8112
2020-12-04 SC 13D/A AMENDMENT NO. 7 0000947871-20-000932 005-88334 201370627 34 81053
2020-11-20 UPLOAD filename1.pdf 0000000000-20-011154 39820
2020-11-20 SC 13D/A AMENDMENT NO. 6 0000947871-20-000897 005-88334 201333006 34 79932
2020-11-20 8-K 8-K 5.03,9.01 0001564590-20-054793 001-36620 201332740 34 262356
2020-11-20 8-K/A 8-K AMENDMENT NO 1 9.01 0001193125-20-298749 001-36620 201330530 34 27811
2020-11-20 DEF 14A DEF 14A 0001193125-20-298745 001-36620 201330525 34 2091570
2020-11-16 10-Q 10-Q 0001564590-20-054210 001-36620 201318143 34 7256778 1
2020-11-13 CORRESP filename1.htm 0001193125-20-293186 33098
2020-11-13 PRER14A PRER14A 0001193125-20-293174 001-36620 201312413 34 2029483
2020-11-09 SC 13G nvus13g.htm 0000935836-20-000603 005-88334 201296852 34 61516
2020-11-09 UPLOAD filename1.pdf 0000000000-20-010686 45556
2020-11-06 4 FORM 4 0001567619-20-018886 19082
2020-11-06 3 FORM 3 0001567619-20-018885 6762
2020-10-23 PRE 14A PRE 14A 0001193125-20-275595 001-36620 201258497 34 1984224
2020-10-14 SC 13D/A AMENDMENT NO. 5 0000947871-20-000795 005-88334 201237893 34 79625
2020-10-06 8-K 8-K 5.03,9.01 0001193125-20-264806 001-36620 201227233 34 29376
2020-10-05 3 OWNERSHIP DOCUMENT 0000921895-20-002529 41398
2020-10-05 SC 13G/A AMENDMENT NO. 1 TO THE SCHEDULE 13G 0000921895-20-002527 005-88334 201224591 34 308482
2020-09-25 D xslFormDX01/primary_doc.xml 06b 0001209191-20-052086 021-376405 201199681 33 13323
2020-09-24 3 FORM 3 SUBMISSION 0000899243-20-026300 19616
2020-09-24 3 FORM 3 SUBMISSION 0000899243-20-026299 13688
2020-09-15 4 FORM 4 SUBMISSION 0000899243-20-025172 6056
2020-09-15 4 FORM 4 SUBMISSION 0000899243-20-025170 6222
2020-09-15 4 FORM 4 SUBMISSION 0000899243-20-025169 6067
2020-09-15 4 FORM 4 SUBMISSION 0000899243-20-025166 6008
2020-09-15 4 FORM 4 SUBMISSION 0000899243-20-025165 6016
2020-09-15 3 FORM 3 SUBMISSION 0000899243-20-025163 7475
2020-09-15 8-K 8-K 1.01,2.01,3.02,5.02,5.03,7.01,9.01 0001193125-20-246314 001-36620 201176766 34 1759474
2020-09-15 424B3 424B3 0001564590-20-043577 333-237379 201175875 33 5968
2020-09-04 8-K 8-K 5.02 0001193125-20-240108 001-36620 201162102 34 18558
2020-08-18 SC 13D/A AMENDMENT NO. 4 0000947871-20-000691 005-88334 201114163 34 81350
2020-08-14 10-Q 10-Q 0001564590-20-040128 001-36620 201100866 34 4825555 1
2020-06-17 8-K 8-K RE TURKEL COHEN DEPARTURES 2.05,5.02 0001564590-20-029654 001-36620 20969771 34 39596
2020-05-15 8-K 8-K 2.02,9.01 0001564590-20-025631 001-36620 20880525 34 205928
2020-05-15 10-Q 10-Q 0001564590-20-025612 001-36620 20880398 34 3908517 1
2020-05-13 8-K 8-K ANNUAL MEETING RESULTS 5.07 0001564590-20-025038 001-36620 20873120 34 77809
2020-04-23 8-K 8-K 3.01 0001564590-20-018029 001-36620 20809099 34 34031
2020-04-03 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2020-04-03 16:01:00 9999999995-20-000680 333-237379 20775626 33 1815
2020-04-02 CORRESP filename1.htm 0001564590-20-014979 13040
2020-03-31 UPLOAD filename1.pdf 0000000000-20-002791 39977
2020-03-31 DEFA14A DEFA14A 0001564590-20-014526 001-36620 20761742 34 208098
2020-03-31 DEF 14A DEF 14A 0001564590-20-014525 001-36620 20761736 34 1258802
2020-03-25 S-8 S-8 0001193125-20-085077 333-237380 20742356 33 79819
2020-03-25 S-1 S-1 0001193125-20-085060 333-237379 20742242 33 270087
2020-03-20 4 FORM 4 SUBMISSION 0000899243-20-009126 5723
2020-03-20 4 FORM 4 SUBMISSION 0000899243-20-009125 5712
2020-03-20 4 FORM 4 SUBMISSION 0000899243-20-009124 5758
2020-03-17 8-K 8-K 2.02,9.01 0001564590-20-011277 001-36620 20719194 34 207378
2020-03-17 10-K 10-K 0001564590-20-011260 001-36620 20718988 34 7476351 1
2020-03-16 PRE 14A PRE 14A 0001564590-20-010887 001-36620 20714393 34 1237910
2020-02-25 4 xslF345X03/ownership.xml 0000947871-20-000146 11278
2020-02-25 4 xslF345X03/ownership.xml 0000947871-20-000145 8608
2020-02-25 SC 13D/A AMENDMENT NO. 3 0000947871-20-000143 005-88334 20651878 34 79313
2020-02-20 8-K/A 8-K/A 3.02,5.03,9.01 0001193125-20-042564 001-36620 20632461 34 24133
2020-02-19 8-K 8-K 3.02,5.03,9.01 0001193125-20-041903 001-36620 20629781 34 120548
2020-02-14 SC 13G/A d8476089_13g-a.htm 0000919574-20-001268 005-88334 20613012 34 143809
2020-02-13 SC 13G/A AMENDMENT NO. 1 TO THE SCHEDULE 13G 0001013594-20-000123 005-88334 20607379 34 81226
2020-02-07 8-K 8-K - NASDAQ DELISTING 3.01 0001564590-20-003758 001-36620 20583957 34 33084
2020-01-27 D xslFormDX01/primary_doc.xml 06b 0001209191-20-004993 021-359033 20549934 33 13143
2020-01-16 424B3 424B3 0001193125-20-009007 333-232011 20531338 33 5187
2020-01-16 8-K 8-K 1.01,3.02,9.01 0001193125-20-008426 001-36620 20529415 34 155562
2020-01-14 424B3 424B3 0001193125-20-007238 333-232011 20526298 33 5074
2019-11-13 8-K 8-K Q3 2019 EARNINGS RELEASE 2.02,9.01 0001564590-19-043080 001-36620 191211569 34 243425
2019-11-13 10-Q 10-Q 0001564590-19-043039 001-36620 191211147 34 3880168 1
2019-09-30 4 FORM 4 SUBMISSION 0000899243-19-024433 5668
2019-09-30 4 FORM 4 SUBMISSION 0000899243-19-024432 5618
2019-09-30 4 FORM 4 SUBMISSION 0000899243-19-024431 5632
2019-08-13 8-K 8-K 2.02,9.01 0001564590-19-031828 001-36620 191021200 34 241389
2019-08-13 10-Q Q2-2019 FORM 10-Q 0001564590-19-031785 001-36620 191020661 34 3894335 1
2019-08-09 8-K 8-K 3.01 0001193125-19-218112 001-36620 191013959 34 18392
2019-07-26 SC 13G SCHEDULE 13G DATED JULY 16, 2019 0001013594-19-000483 005-88334 19977589 34 81236
2019-07-15 4 FORM 4 SUBMISSION 0000899243-19-019601 5272
2019-07-15 4 FORM 4 SUBMISSION 0000899243-19-019600 5264
2019-07-15 4 FORM 4 SUBMISSION 0000899243-19-019599 5222
2019-07-15 4 FORM 4 SUBMISSION 0000899243-19-019598 5312
2019-07-15 4 FORM 4 SUBMISSION 0000899243-19-019597 5256
2019-07-12 8-K 8-K 4.01,5.02,9.01 0001193125-19-193205 001-36620 19953122 34 75036
2019-06-28 S-8 S-8 0001193125-19-185998 333-232428 19929309 33 121910
2019-06-17 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2019-06-17 16:01:00 9999999995-19-001363 333-232011 19902570 33 1815
2019-06-14 CORRESP filename1.htm 0001193125-19-173656 6891
2019-06-12 UPLOAD filename1.pdf 0000000000-19-009796 39912
2019-06-07 S-1 S-1 0001193125-19-168171 333-232011 19885758 33 252173
2019-06-05 SC 13G d8237203_13-g.htm 0000919574-19-003970 005-88334 19879555 34 118565
2019-05-22 4 PRIMARY DOCUMENT 0001562180-19-003055 7339
2019-05-22 4 PRIMARY DOCUMENT 0001562180-19-003052 7336
2019-05-22 4 PRIMARY DOCUMENT 0001562180-19-003051 7351
2019-05-15 DEFA14A DEFA14A 0001564590-19-019437 001-36620 19828831 34 176257
2019-05-15 DEF 14A DEF 14A 0001564590-19-019430 001-36620 19828719 34 982518
2019-05-14 8-K 8-K 2.02,9.01 0001564590-19-019162 001-36620 19823187 34 255780
2019-05-14 10-Q 10-Q MARCH 31, 2019 0001564590-19-019134 001-36620 19822708 34 3416519 1
2019-05-10 SC 13G THE SCHEDULE 13G 0000921895-19-001354 005-88334 19815286 34 229060
2019-05-10 D xslFormDX01/primary_doc.xml 06b 0001209191-19-028847 021-339368 19814779 33 13210
2019-05-06 4 xslF345X03/ownership.xml 0000947871-19-000337 13092
2019-05-06 4 xslF345X03/ownership.xml 0000947871-19-000336 10358
2019-05-06 SC 13D/A AMENDMENT NO. 2 0000947871-19-000328 005-88334 19800125 34 125749
2019-05-02 4 xslF345X03/ownership.xml 0000919574-19-003096 6967
2019-05-02 8-K 8-K 1.01,3.02,8.01,9.01 0001193125-19-135059 001-36620 19792257 34 405117
2019-05-01 424B5 424B5 0001193125-19-130755 333-226286 19784642 33 371616
2019-04-30 10-K/A 10-K/A 0001193125-19-129270 001-36620 19781646 34 290574
2019-04-22 8-K 8-K CLINICAL RESULTS 8.01,9.01 0001564590-19-012158 001-36620 19758664 34 76220
2019-04-05 SC 13D/A SC 13D/A 0001104659-19-020047 005-88334 19733483 34 222521
2019-03-28 8-K 8-K 2.02,9.01 0001564590-19-009676 001-36620 19709840 34 246441
2019-03-28 10-K 10-K 0001564590-19-009631 001-36620 19709318 34 8289473 1
2019-03-18 4 FORM 4 SUBMISSION 0000899243-19-008141 8203
2019-03-18 4 FORM 4 SUBMISSION 0000899243-19-008140 7524
2019-03-18 4 FORM 4 SUBMISSION 0000899243-19-008139 5672
2019-01-08 8-K 8-K CORPORATE PRESENTATION 7.01,9.01 0001564590-19-000367 001-36620 19515283 34 5842250
2018-11-13 8-K 8-K Q3 2018 EARNING RELEASE 2.02,9.01 0001564590-18-029134 001-36620 181175195 34 232128
2018-11-13 10-Q 10-Q 0001564590-18-028982 001-36620 181174272 34 3927497 1
2018-09-13 4 FORM 4 SUBMISSION 0000899243-18-024470 7791
2018-09-07 4 FORM 4 SUBMISSION 0000899243-18-024043 5339
2018-09-07 RW RW 0001193125-18-268697 333-226467 181058955 NE 6943
2018-09-04 S-1/A S-1/A 0001193125-18-266270 333-226467 181052779 33 541228
2018-08-07 8-K 8-K 2.02,9.01 0001564590-18-019667 001-36620 18996385 34 227827
2018-08-07 10-Q 10-Q 0001564590-18-019519 001-36620 18995758 34 4249816 1
2018-08-01 S-1 S-1 0001193125-18-233511 333-226467 18982301 33 331070
2018-07-31 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2018-07-31 16:00:00 9999999995-18-001961 333-226286 18982849 33 1815
2018-07-31 UPLOAD filename1.pdf 0000000000-18-023476 44842
2018-07-30 CORRESP filename1.htm 0001193125-18-231910 6210
2018-07-23 S-3 S-3 0001193125-18-223696 333-226286 18964581 33 1089467
2018-06-14 4 FORM 4 SUBMISSION 0000899243-18-016655 5253
2018-06-14 4 FORM 4 SUBMISSION 0000899243-18-016654 5309
2018-06-14 4 FORM 4 SUBMISSION 0000899243-18-016653 5261
2018-06-14 4 FORM 4 SUBMISSION 0000899243-18-016652 5269
2018-06-14 8-K 8-K 5.07 0001564590-18-015631 001-36620 18900100 34 51335
2018-05-15 SC 13D/A SCHEDULE 13D/A - AMENDMENT NO. 3 (EXIT FILING) 0001072613-18-000344 005-88334 18836859 34 247503
2018-05-11 8-K 8-K FOR Q1 2018 EARNINGS RELEASE 2.02,9.01 0001564590-18-013100 001-36620 18824575 34 192083
2018-05-11 10-Q 10-Q 0001564590-18-013090 001-36620 18824550 34 3505347 1
2018-05-02 SC 13D/A SCHEDULE 13D/A - AMENDMENT NO. 2 0001072613-18-000306 005-88334 18800677 34 244698
2018-04-30 DEFA14A DEFA14A 0001564590-18-009751 001-36620 18788222 34 147475
2018-04-30 DEF 14A DEF 14A 0001564590-18-009747 001-36620 18788144 34 1095124
2018-04-17 SC 13D/A SC 13D/A 0001193125-18-119824 005-88334 18759233 34 91770
2018-04-02 8-K 8-K Q4 2017 EARNINGS RELEASE 2.02,9.01 0001564590-18-007316 001-36620 18727086 34 201948
2018-04-02 10-K 10-K 0001564590-18-007314 001-36620 18727081 34 8246739 1
2018-03-20 3 OWNERSHIP DOCUMENT 0000919574-18-002573 6068
2018-03-19 SC 13D/A AMENDMENT NO. 1 0000947871-18-000249 005-88334 18698575 34 102321
2018-03-15 4 FORM 4 SUBMISSION 0000899243-18-007648 7648
2018-03-15 4 FORM 4 SUBMISSION 0000899243-18-007647 7610

Latest XBRL company facts

One latest value per concept from companyfacts (326 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 84.46M 2026-11-10 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
dei EntityPublicFloat Entity Public Float USD 145.17M 2025-06-30 2025 FY 10-K 2026-03-19 0001193125-26-116164
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD -290,407 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-197732
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 1.64M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-197732
ecd PeoActuallyPaidCompAmt PeoActuallyPaidCompAmt USD -315,000 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-197732
ecd PeoTotalCompAmt PeoTotalCompAmt USD 3.22M 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-197732
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 66.23 2025-01-01 2025-12-31 DEF 14A 2026-04-30 0001193125-26-197732
ffd NetFeeAmt NetFeeAmt USD 1,575.72 2026-09-04 S-8 2026-09-04 0001193125-26-383824
ffd TtlFeeAmt TtlFeeAmt USD 1,575.72 2026-09-04 S-8 2026-09-04 0001193125-26-383824
ffd TtlOfferingAmt TtlOfferingAmt USD 11.41M 2026-09-04 S-8 2026-09-04 0001193125-26-383824
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-09-04 S-8 2026-09-04 0001193125-26-383824
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-04-28 S-3 2026-05-01 0001193125-26-201426
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 2.84M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD -1,000 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap AccruedLiabilitiesAndOtherLiabilities Accrued Liabilities and Other Liabilities USD 8.52M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 1.49M 2017-06-30 2017 Q2 10-Q 2017-08-09 0001193125-17-252847
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 357,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap AccruedVacationCurrent Accrued Vacation, Current USD 148,000 2021-09-30 2021 Q3 10-Q 2021-11-12 0001564590-21-056417
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 130,000 2016-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -126,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 190.49M 2015-03-31 2015 Q1 10-Q 2015-05-12 0001193125-15-182900
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 506.63M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap AdditionalPaidInCapitalPreferredStock Additional Paid in Capital, Preferred Stock USD 420.93M 2025-03-31 2025 Q1 10-Q/A 2025-08-14 0001193125-25-180904
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 1.92M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 3.33M 2014-01-01 2014-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation USD 1.40M 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 7.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap AllowanceForLoanAndLeaseLossesAdjustmentsNet Allowance for Loan and Lease Losses, Adjustments, Other USD 49,000 2015-01-01 2015-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 10.85M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap Assets Assets USD 106.64M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap AssetsCurrent Assets, Current USD 73.71M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 531,000 2016-12-31 2017 FY 10-K 2018-04-02 0001564590-18-007314
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 36,000 2025-12-31 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 126,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 62.92M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 62.79M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) USD -55,000 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-10 0001193125-16-499163
us-gaap BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax USD -11.84M 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-28 0001564590-19-009631
us-gaap BusinessAcquisitionsProFormaNetIncomeLoss Business Acquisition, Pro Forma Net Income (Loss) USD -11.79M 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-28 0001564590-19-009631
us-gaap BusinessAcquisitionsProFormaRevenue Business Acquisition, Pro Forma Revenue USD 120,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap BusinessCombinationAcquisitionRelatedCosts Business Combination, Acquisition Related Costs USD 0 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-12 0001564590-21-056417
us-gaap BusinessExitCosts1 Business Exit Costs USD 133,000 2015-01-01 2015-09-30 2016 Q3 10-Q 2016-11-03 0001193125-16-757930
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 98,000 2015-01-01 2015-09-30 2016 Q3 10-Q 2016-11-03 0001193125-16-757930
us-gaap Cash Cash USD 8.76M 2020-06-30 2020 Q2 10-Q 2020-08-14 0001564590-20-040128
us-gaap CashAcquiredFromAcquisition Cash Acquired from Acquisition USD 11.04M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 6.88M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD 1.18M 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 69.70M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 6.88M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -15.93M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap CashEquivalentsAtCarryingValue Cash Equivalents, at Carrying Value USD 9.40M 2023-03-31 2023 Q1 10-Q 2023-05-11 0000950170-23-021372
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 0.001 2023-12-31 2023 FY 10-K/A 2024-08-19 0000950170-24-098575
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 20.96M 2024-03-31 2024 Q1 10-Q/A 2024-08-19 0000950170-24-098582
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 450.00M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 81.44M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 81.44M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap CommonStockValue Common Stock, Value, Issued USD 82,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -74.74M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 85.34M 2014-01-01 2014-09-30 2014 Q3 10-Q 2014-11-13 0001193125-14-411225
us-gaap ConversionOfStockAmountIssued1 Conversion of Stock, Amount Issued USD 4,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ConversionOfStockSharesConverted1 Conversion of Stock, Shares Converted shares 3,285 2020-06-01 2020-06-10 2020 Q3 10-Q 2020-11-16 0001564590-20-054210
us-gaap ConvertibleDebt Convertible Debt USD 0 2017-09-30 2017 Q3 10-Q 2017-11-08 0001564590-17-022799
us-gaap ConvertibleNotesPayableCurrent Convertible Notes Payable, Current USD 0 2017-12-31 2017 FY 10-K 2018-04-02 0001564590-18-007314
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 14.86M 2014-09-30 2014 FY 10-K 2015-03-26 0001193125-15-107051
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 30,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 30,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap DebtInstrumentFairValue Debt Instrument, Fair Value Disclosure USD 3.40M 2016-12-31 2017 FY 10-K 2018-04-02 0001564590-18-007314
us-gaap DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction USD 98,000 2014-01-01 2014-03-31 2015 Q1 10-Q 2015-05-12 0001193125-15-182900
us-gaap DebtLongtermAndShorttermCombinedAmount Debt, Long-term and Short-term, Combined Amount USD 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD -2.75M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-30 0000950170-23-011011
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD 5,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 7.77M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap DeferredIncomeTaxLiabilitiesNet Deferred Income Tax Liabilities, Net USD 2.19M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 30,000 2013-12-31 2014 FY 10-K 2015-03-26 0001193125-15-107051
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD 5,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 68.59M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 28.23M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 0 2016-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap DeferredTaxAssetsNetCurrent Deferred Tax Assets, Net of Valuation Allowance, Current USD 414,000 2014-12-31 2014 FY 10-K 2015-03-26 0001193125-15-107051
us-gaap DeferredTaxAssetsNetNoncurrent Deferred Tax Assets, Net of Valuation Allowance, Noncurrent USD 32.86M 2014-12-31 2014 FY 10-K 2015-03-26 0001193125-15-107051
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 29.51M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsDomestic Deferred Tax Assets, Operating Loss Carryforwards, Domestic USD 27.90M 2015-12-31 2015 FY 10-K 2016-03-10 0001193125-16-499163
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal Deferred Tax Assets, Operating Loss Carryforwards, State and Local USD 24.20M 2015-12-31 2015 FY 10-K 2016-03-10 0001193125-16-499163
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 44,000 2016-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 7.62M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 1.59M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals USD 699,000 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities USD 207,000 2016-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 63.01M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 2.19M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap DefinedBenefitPlanContributionsByEmployer Defined Benefit Plan, Plan Assets, Contributions by Employer USD 400,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 19,000 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap Depreciation Depreciation USD 17,000 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 5,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap DilutiveSecuritiesEffectOnBasicEarningsPerShareOther Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities USD 1.66B 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-12 0000950170-24-125622
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.63 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.69 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0001564590-22-019921
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.63 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.324 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.078 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0.001 2015-01-01 2015-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap EffectiveIncomeTaxRateReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Percent pure -0.039 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.077 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 186,000 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount USD 13.80M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD 11.56M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap FairValueAssetsLevel1ToLevel2TransfersAmount Fair Value, Assets, Level 1 to Level 2 Transfers, Amount USD 0 2021-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap FairValueAssetsLevel2ToLevel1TransfersAmount Fair Value, Assets, Level 2 to Level 1 Transfers, Amount USD 0 2021-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap FairValueLiabilitiesLevel1ToLevel2TransfersAmount Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount USD 0 2021-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap FairValueLiabilitiesLevel2ToLevel1TransfersAmount Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount USD 0 2021-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap FairValueOfAssetsAcquired Fair Value of Assets Acquired USD 3.07M 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-28 0001564590-19-009631
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD -49,000 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-28 0001564590-19-009631
us-gaap GainLossOnTerminationOfLease Gain (Loss) on Termination of Lease USD 10,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt USD -517,000 2016-01-01 2016-12-31 2017 FY 10-K 2018-04-02 0001564590-18-007314
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 12.53M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap Goodwill Goodwill USD 0 2023-12-31 2023 FY 10-K/A 2024-08-19 0000950170-24-098575
us-gaap GoodwillAcquiredDuringPeriod Goodwill, Acquired During Period USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap GoodwillAndIntangibleAssetImpairment Goodwill and Intangible Asset Impairment USD 0 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-16 0001564590-20-054210
us-gaap GoodwillGross Goodwill, Gross USD 48.65M 2021-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap GoodwillImpairedAccumulatedImpairmentLoss Goodwill, Impaired, Accumulated Impairment Loss USD 1.87M 2019-12-31 2019 FY 10-K 2020-03-17 0001564590-20-011260
us-gaap GoodwillImpairmentLoss Goodwill, Impairment Loss USD 0 2023-01-01 2023-12-31 2023 FY 10-K/A 2024-08-19 0000950170-24-098575
us-gaap GuaranteeObligationsCurrentCarryingValue Guarantor Obligations, Current Carrying Value USD 0 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use USD 0 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-08-14 0001193125-25-180865
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -45.78M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -45.58M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD 199,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest USD -23.21M 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-31 0001564590-21-016828
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 28,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap IncomeTaxExaminationPenaltiesAndInterestAccrued Income Tax Examination, Penalties and Interest Accrued USD 0 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 35,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 14.75M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap IncomeTaxReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount USD 1.86M 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-28 0001564590-19-009631
us-gaap IncomeTaxReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount USD 59,000 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-28 0001564590-19-009631
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -9.57M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount USD 0 2023-01-01 2023-12-31 2023 FY 10-K/A 2024-08-19 0000950170-24-098575
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 12,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 3.57M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 24,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 35,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap IncomeTaxReconciliationTaxContingencies Effective Income Tax Rate Reconciliation, Tax Contingency, Amount USD 1.76M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap IncomeTaxReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Amount USD 2.36M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 3.51M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -154,000 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities USD 2.08M 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-30 0000950170-23-011011
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD -246,000 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -265,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD 45,000 2015-01-01 2015-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap IncreaseDecreaseInOtherOperatingLiabilities Increase (Decrease) in Other Operating Liabilities USD -36,000 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 1.55M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap IncreaseDecreaseInRestrictedCash Increase (Decrease) in Restricted Cash USD -150,000 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap InsuranceSettlementsReceivableCurrent Insurance Settlements Receivable, Current USD 110,000 2020-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap InterestAndOtherIncome Interest and Other Income USD 26,000 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap InvestmentIncomeAmortizationOfPremium Investment Income, Amortization of Premium USD 34,000 2015-01-01 2015-09-30 2015 Q3 10-Q 2015-11-10 0001193125-15-372762
us-gaap InvestmentsAndCash Investments and Cash USD 27.40M 2016-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap InvestmentsFairValueDisclosure Investments, Fair Value Disclosure USD 22.94M 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap LeaseAndRentalExpense Operating Leases, Rent Expense USD 189,000 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-12 0001564590-21-056417
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 395,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 294,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 293,000 2024-12-31 2024 FY 10-K/A 2025-08-14 0001193125-25-180865
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 294,000 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 101,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 19,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap Liabilities Liabilities USD 36.83M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 106.64M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap LiabilitiesAssumed1 Liabilities Assumed USD 2.95M 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-28 0001564590-19-009631
us-gaap LiabilitiesCurrent Liabilities, Current USD 11.70M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap LiabilitiesFairValueDisclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure USD 3.45M 2016-12-31 2017 FY 10-K 2018-04-02 0001564590-18-007314
us-gaap LiabilitiesNoncurrent Liabilities, Noncurrent USD 94,000 2017-09-30 2017 Q3 10-Q 2017-11-08 0001564590-17-022799
us-gaap MarketableSecurities Marketable Securities USD 0 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD -180,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 7.49M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-11 0001564590-18-013090
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 48.52M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD 23.26M 2017-01-01 2017-12-31 2017 FY 10-K 2018-04-02 0001564590-18-007314
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -64.27M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD -2.27M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-11 0001564590-18-013090
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -74.59M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -71.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Net Income (Loss) Available to Common Stockholders, Diluted USD -71.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 166,000 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-26 0001193125-15-107051
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap NumberOfReportingUnits Number of Reporting Units Reporting_Unit 1 2023-01-01 2023-12-31 2023 FY 10-K/A 2024-08-19 0000950170-24-098575
us-gaap OperatingExpenses Operating Expenses USD 65.72M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -65.72M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OperatingLeaseCost Operating Lease, Cost USD 298,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 300,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 376,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 341,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 35,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OperatingLeasePayments Operating Lease, Payments USD 301,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 358,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OperatingLeaseRightOfUseAssetAmortizationExpense Operating Lease, Right-of-Use Asset, Amortization Expense USD 359,000 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-08-14 0001193125-25-180865
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 514,000 2018-12-31 2019 FY 10-K 2020-03-17 0001564590-20-011260
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 180,000 2018-12-31 2019 FY 10-K 2020-03-17 0001564590-20-011260
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 152,000 2018-09-30 2018 Q3 10-Q 2018-11-13 0001564590-18-028982
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 146,000 2018-12-31 2019 FY 10-K 2020-03-17 0001564590-20-011260
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 188,000 2018-12-31 2019 FY 10-K 2020-03-17 0001564590-20-011260
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 46,000 2018-09-30 2018 Q3 10-Q 2018-11-13 0001564590-18-028982
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.094 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 42,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OtherAssetsCurrent Other Assets, Current USD 497,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 185,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent USD 1,000 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD -12,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD 1,000 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax USD -150,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 126,000 2016-03-31 2016 Q1 10-Q 2016-05-10 0001193125-16-584673
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD 2.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap OtherPrepaidExpenseCurrent Other Prepaid Expense, Current USD 169,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap PaymentsForRestructuring Payments for Restructuring USD 2.27M 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-31 0001564590-21-016828
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 450,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-30 0000950170-23-011011
us-gaap PaymentsRelatedToTaxWithholdingForShareBasedCompensation Payment, Tax Withholding, Share-based Payment Arrangement USD 903,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Payments to Acquire Debt Securities, Available-for-sale USD 68.75M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 500,000 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 9,000 2016-01-01 2016-12-31 2017 FY 10-K 2018-04-02 0001564590-18-007314
us-gaap PostemploymentBenefitsLiabilityCurrent Postemployment Benefits Liability, Current USD 668,000 2017-12-31 2018 FY 10-K 2019-03-28 0001564590-19-009631
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2024-12-31 2024 FY 10-K/A 2025-08-14 0001193125-25-180865
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 5.00M 2024-12-31 2024 FY 10-K/A 2025-08-14 0001193125-25-180865
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 511 2020-09-30 2020 Q3 10-Q 2020-11-16 0001564590-20-054210
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 511 2020-09-30 2020 Q3 10-Q 2020-11-16 0001564590-20-054210
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 19,000 2016-12-31 2017 FY 10-K 2018-04-02 0001564590-18-007314
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 4.04M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap PrepaidInsurance Prepaid Insurance USD 78,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap PrepaidInterest Prepaid Interest USD 544,000 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap ProceedsFromConvertibleDebt Proceeds from Convertible Debt USD 2.93M 2016-01-01 2016-12-31 2017 FY 10-K 2018-04-02 0001564590-18-007314
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 97.93M 2014-01-01 2014-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 9.00M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Proceeds from Issuance of Preferred Stock and Preference Stock USD 95.23M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock Proceeds from Issuance of Redeemable Convertible Preferred Stock USD 35.41M 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-10 0001193125-16-499163
us-gaap ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale USD 117.28M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 4.17M 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap ProceedsFromSaleOfMachineryAndEquipment Proceeds from Sale of Machinery and Equipment USD 8,000 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-28 0001564590-19-009631
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 333,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap ProceedsFromWarrantExercises Proceeds from Warrant Exercises USD 390,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap ProfessionalFees Professional Fees USD 1.05M 2014-01-01 2014-09-30 2014 Q3 10-Q 2014-11-13 0001193125-14-411225
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 228,000 2016-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 5,000 2019-12-31 2020 FY 10-K 2021-03-31 0001564590-21-016828
us-gaap PurchaseObligation Purchase Obligation USD 20.70M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap RepaymentOfNotesReceivableFromRelatedParties Repayment of Notes Receivable from Related Parties USD 49,000 2015-01-01 2015-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 53.19M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap RestrictedCashAndCashEquivalentsAtCarryingValue Restricted Cash and Cash Equivalents, Current USD 10.10M 2020-09-30 2020 Q3 10-Q 2020-11-16 0001564590-20-054210
us-gaap RestrictedCashAndCashEquivalentsNoncurrent Restricted Cash and Cash Equivalents, Noncurrent USD 70,000 2017-09-30 2017 Q3 10-Q 2017-11-08 0001564590-17-022799
us-gaap RestrictedCashCurrent Restricted Cash, Current USD 0 2018-12-31 2018 FY 10-K 2019-03-28 0001564590-19-009631
us-gaap RestrictedStockValueSharesIssuedNetOfTaxWithholdings Restricted Stock, Value, Shares Issued Net of Tax Withholdings USD -903,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent pure 0.6 2016-07-01 2016-09-30 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap RestructuringCharges Restructuring Charges USD 2.30M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap RestructuringReserve Restructuring Reserve USD 12,000 2020-12-31 2020 FY 10-K 2021-03-31 0001564590-21-016828
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -475.79M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap Revenues Revenues USD 0 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 344,000 2022-01-01 2022-12-31 2023 FY 10-K/A 2024-08-19 0000950170-24-098575
us-gaap SalesRevenueGoodsNet Sales Revenue, Goods, Net (Deprecated 2018-01-31) USD 0 2017-01-01 2017-03-31 2017 Q1 10-Q 2017-05-03 0001193125-17-156191
us-gaap SeveranceCosts1 Severance Costs USD 1.04M 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 2.11M 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-26 0001193125-15-107051
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.978 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.984 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-12 0000950170-24-125622
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.935 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-12 0000950170-24-125622
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.045 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.039 2023-01-01 2023-12-31 2024 Q3 10-Q 2024-11-12 0000950170-24-125622
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.038 2023-01-01 2023-12-31 2024 Q3 10-Q 2024-11-12 0000950170-24-125622
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 179,000 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 9.19M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 3.31 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 200,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period shares 6,710 2016-01-01 2016-12-31 2017 FY 10-K 2018-04-02 0001564590-18-007314
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 2.80M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 8.66 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 8,074 2016-01-01 2016-12-31 2017 FY 10-K 2018-04-02 0001564590-18-007314
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 2.50M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 3.25 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 357,000 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 15.23M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 3.17 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 357,000 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 15.23M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 3.17 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 2.3 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price USD/shares 19.75 2016-01-01 2016-12-31 2017 FY 10-K 2018-04-02 0001564590-18-007314
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 19.01 2016-01-01 2016-12-31 2017 FY 10-K 2018-04-02 0001564590-18-007314
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 4.01 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap SharePrice Share Price USD/shares 2.49 2024-09-30 2024 Q3 10-Q 2024-11-12 0000950170-24-125622
us-gaap SharesOutstanding Shares, Outstanding shares 6,204 2021-06-30 2021 Q2 10-Q 2021-08-12 0001564590-21-044038
us-gaap ShortTermInvestments Short-term Investments USD 62.79M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 30.80M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.056 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap StockIssued1 Stock Issued USD 598,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Stock Issued During Period, Shares, Conversion of Convertible Securities shares -3,285 2020-01-01 2020-06-30 2021 Q2 10-Q 2021-08-12 0001564590-21-044038
us-gaap StockIssuedDuringPeriodSharesReverseStockSplits Stock Issued During Period, Shares, Reverse Stock Splits shares 840,115 2017-05-08 2017-05-09 2018 FY 10-K 2019-03-28 0001564590-19-009631
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 100,437 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap StockIssuedDuringPeriodValueAcquisitions Stock Issued During Period, Value, Acquisitions USD 1.19M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 16.68M 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 8.55M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardGross Stock Issued During Period, Value, Restricted Stock Award, Gross USD 0 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-03 0001193125-17-069741
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 242,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap TangibleAssetImpairmentCharges Tangible Asset Impairment Charges USD 0 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-16 0001564590-20-054210
us-gaap TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap TemporaryEquityAccretionToRedemptionValueAdjustment Temporary Equity, Accretion to Redemption Value, Adjustment USD 94,000 2013-01-01 2013-12-31 2015 FY 10-K 2016-03-10 0001193125-16-499163
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 164.95M 2020-09-30 2020 Q3 10-Q 2020-11-16 0001564590-20-054210
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 83.53M 2013-12-31 2014 FY 10-K 2015-03-26 0001193125-15-107051
us-gaap TemporaryEquityParOrStatedValuePerShare Temporary Equity, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 5.00M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 339,138 2020-09-30 2020 Q3 10-Q 2020-11-16 0001564590-20-054210
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 339,138 2020-09-30 2020 Q3 10-Q 2020-11-16 0001564590-20-054210
us-gaap TemporaryEquityStockIssuedDuringPeriodValueNewIssues Temporary Equity, Stock Issued During Period, Value, New Issues USD 95.23M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-24 0001564590-22-011698
us-gaap UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic Undistributed Earnings (Loss) Allocated to Participating Securities, Basic USD 2.88M 2024-01-01 2024-09-30 2025 Q3 10-Q 2025-11-14 0001193125-25-283275
us-gaap UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted USD 2.03M 2024-01-01 2024-09-30 2025 Q3 10-Q 2025-11-14 0001193125-25-283275
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 8.02M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions USD 7,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-30 0000950170-23-011011
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 2.02M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 12,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Unrecognized Tax Benefits that Would Impact Effective Tax Rate USD 0 2019-09-30 2019 Q3 10-Q 2019-11-13 0001564590-19-043039
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 16.60M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-116164
us-gaap VariableInterestEntityActivityBetweenVIEAndEntityExpense Variable Interest Entity, Measure of Activity, Expense USD 8,000 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-26 0001193125-15-107051
us-gaap VariableInterestEntityOwnershipPercentage Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage pure 0 2015-01-01 2015-12-31 2015 FY 10-K 2016-03-10 0001193125-16-499163
us-gaap WarrantsAndRightsOutstanding Warrants and Rights Outstanding USD 22.90M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 113.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 14.33M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0001564590-22-019921
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 113.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564
us-gaap WorkersCompensationLiabilityCurrent Workers' Compensation Liability, Current USD 3.34M 2026-09-30 2026 Q3 10-Q 2026-11-12 0001193125-26-458564

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →